Log In
Print
BCIQ
Print
Print this Print this
 

trastuzumab (ABP 980)

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionBiosimilar to trastuzumab
Molecular Target Epidermal growth factor receptor 2 (EGFR2) (HER2) (ErbB2) (neu)
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationBreast cancer
Indication DetailsTreat HER2-positive breast cancer
Regulatory Designation

Partner

Actavis plc


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today